Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10008

Result Summary for APV10008

Result Summary

Protocol ID:	APV10008
Clinical Study ID:	APV10008
Official Title:	A Phase I, Single-dose, Open-label, Randomized, Four-period, Balanced Crossover Study to Assess the Relative Bioavailability of the GW433908 Oral Suspension Relative to the GW433908 Oral Film-coated 700mg Tablet and to Assess the Effects of Food on Amprenavir Pharmacokinetics Following Administr ...
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	lexiva;lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Pharmacokinetics of gw433908, a prodrug of amprenavir, in healthy male volunteers. Falcoz, C., Jenkins, J. M., Bye, C., Hardman, T. C., Kenney, K. B., Studenberg, S., Fuder, H., and Prince, W. T. J Clin Pharmacol 2002; 42(8):887-98 M.B. Wire, Y. Lou, M.J. Shelton, P. Mydlow, K.H.P. Moore. Evaluation of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Fosamprenavir (FPV) Formulations with a High Fat Breakfast (HFB) (APV10008). 44th ICAAC, 2004.